Chinese ADR delisting threat looms over ETFs
中概股退市风险为相关ETF蒙上阴影
More than 95% of one Invesco ETF is in Chinese ADRs and an iShares ETF is the largest holder of five facing delisting
由于在美上市的中国企业可能因为不满足美国审计要求而退市，贝莱德、景顺等基金公司管理的中概股ETF面临很大的风险关口。
The US Securities and Exchange Commission has moved closer to delisting certain Chinese companies, identifying the first batch of five that will have to provide proof of audit compliance by the end of March. Failing to do so means they will have to delist from New York’s stock exchange by 2024.
美国证交会(SEC)朝着摘牌某些中国企业又迈进一步，列出了首批五家必须在3月底之前提供审计合规证据的中国企业。这些企业如果一直不能提供证据，就只能不晚于2024年从纽约相关交易所退市。
The five companies are Yum China, ACM Research, BeiGene, HutchMed and Zai Lab.
这五家企业是百胜中国(Yum China)、盛美半导体(ACM Research)、百济神州(BeiGene)、和黄医药(HutchMed)和再鼎医药(Zai Lab)。
